Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV
Frédérique Chammartin, Katharina Kusejko, Chloé Pasin, Alexandra Trkola, Matthias Briel, Patrizia Amico, Marcel P. Stoekle, Anna Eichenberger, Barbara Hasse, Dominique L. Braun, Macé M. Schuurmans, Thomas F. Müller, Michael Tamm, Nicolas J. Mueller, Andri Rauch, Michael Koller, Huldrych F. Günthard, Heiner C. Bucher, Benjamin Speich, Irène A. Abela
Abstract
We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4+ cell count superior to 350 cells/μl and vaccinated with mRNA-1273 by Moderna compared with BNT162b2 by Pfizer-BioNTech. Preinfection with SARS-CoV-2 boosted the antibody response and smokers had an overall lower antibody response. Elderly PWH and those with low CD4+ cell count should be prioritized for booster vaccinations.